Work

Evaluación de Biomarcadores PSA, PCT, CEA y HCG-β en la Hiperplasia Prostática Benigna como herramientas diagnósticas

Year: 2025
Type: article
Study design: Observational Study
Abstract: Benign prostatic hyperplasia (BPH) is one of the most common urological disorders in men over 50 years of age and represents a major public health concern due to its impact on quality of life and the challenges it poses in the differential diagnosis with prostate cancer. Traditionally, prostate-specific antigen (PSA) has been the most widely used biomarker for the evaluation of these conditions; however, its low specificity may lead to overdiagnosis and unnecessary invasive procedures. In this context, the present study aimed to assess the usefulness of emerging biomarkers such as procalcitonin (PCT), carcinoembryonic antigen (CEA), and the beta subunit of human chorionic gonadotropin (HCG-β) as complementary tools to PSA in the differential diagnosis of BPH and prostate cancer. An analytical cross-sectional study was conducted in 369 patients treated at the Japanese Hospital in Santa Cruz, Bolivia, divided into three groups: BPH, prostate cancer, and healthy controls. Biomarkers were analysed using chemiluminescence immunoassay (CLIA) with the automated Maglumi 800 system. The results showed that PSA retained the highest discriminative capacity (AUC=0.996), while PCT demonstrated moderate performance (AUC=0.733), and HCG-β revealed significant differences between cancer and BPH, although with high variability. By contrast, CEA did not show statistical significance among the groups. In conclusion, the combination of PSA with emerging biomarkers could significantly improve diagnostic accuracy and reduce the need for invasive biopsies, although further studies are required to validate its clinical applicability and strengthen its utility in medical practice.
Language: Spanish
Subfield: Urology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W4414342986
FWCI:
Cites: 1
Cited by:
Related to: 10